Ergoteles’s Oculis Holding OCS Stock Holding History

Ergoteles’s Portfolio OCS Stock Details OCS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20,000	Closed	-$247K	–	585
2023 Q2	$247K	Buy	+20,000	New	+$223K	0.01%	815

Other funds holding OCS

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $8.13B AUM 26.03% 1-Year Est. Return

Bank of America

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Elequin Capital New York $1.19B AUM 16.08% 1-Year Est. Return

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Dupont Capital Management Wilmington, Delaware $879M AUM 29.99% 1-Year Est. Return

Ergoteles's OCS Position: Q3 2023 in Review

Ergoteles sold out of Oculis Holding (OCS) in Q3 2023, closing a stake of 20,000 shares — an estimated $247K sold.

Ergoteles first reported a position in OCS in Q2 2023 and held it in 1 quarter. The position peaked at $247K in Q2 2023. 9 funds tracked by Wall St. Rank hold OCS as of Q3 2023.

Ergoteles reported no remaining Oculis Holding position as of Q3 2023 after selling out during the quarter.
Ergoteles sold 20,000 Oculis Holding shares in Q3 2023, an estimated $247K.
Ergoteles first reported a position in Oculis Holding in Q2 2023 and held it in 1 quarter.
Ergoteles's Oculis Holding position peaked at $247K in Q2 2023.
9 funds tracked by Wall St. Rank held Oculis Holding as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.